
ERIS Lifesciences Ltd is Rated Sell by MarketsMOJO
2026-11-21 10:10:33ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 November 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and technical outlook.
Read More
ERIS Lifesciences Ltd is Rated Sell
2026-11-10 10:10:30ERIS Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 27 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 November 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read MoreERIS Lifesciences Gains 6.25%: Valuation and Technical Shifts Shape Weekly Momentum
2026-11-07 13:04:35Key Events This Week 2 Nov: Stock opens at Rs.1,163.25, Sensex up 1.57% 3 Nov: Strong volume surge accompanies 1.22% price rise 4 Nov: Valuation shift noted as stock gains 3.40% 5 Nov: Technical momentum shifts amid mixed signals 6 Nov: Week closes at Rs.1,232.05, up 0.17% on day Week OpenRs.1,159.60 <di...
Read More
ERIS Lifesciences Ltd Valuation Shifts Amid Mixed Market Returns
2026-11-05 08:03:03ERIS Lifesciences Ltd has experienced a notable shift in its valuation parameters, moving from an attractive to a fair rating as of late October 2026. This change reflects evolving market perceptions amid a challenging sector environment and relative to its pharmaceutical peers. Despite a recent 3.4% intraday price gain, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more cautious outlook from investors.
Read MoreERIS Lifesciences Gains 5.64%: Four Key Factors Driving the Week’s Volatility
2026-10-31 14:00:38Key Events This Week 26 Oct: Stock hits 52-week low at Rs.1,069 amid market pressure 27 Oct: Intraday high surge of 7.43% to Rs.1,193.05 28 Oct: Quality grade downgraded from good to average 28 Oct: Valuation grade upgraded from very attractive to attractive 30 Oct: Week closes at Rs.1,159.60, up 5.64% for the week Week OpenRs.1,097.65 ...
Read More
ERIS Lifesciences Ltd is Rated Sell
2026-10-30 10:10:48ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 October 2026. However, the analysis below reflects the stock's current position as of 30 October 2026, incorporating the latest fundamentals, returns, and financial metrics to provide investors with an up-to-date perspective.
Read More
ERIS Lifesciences Ltd: Valuation Shift Enhances Price Attractiveness Amid Mixed Returns
2026-10-28 08:00:57ERIS Lifesciences Ltd has witnessed a notable improvement in its valuation parameters, prompting a revision in its investment grade from Sell to Hold. With its price-to-earnings (P/E) ratio now at 21.83 and price-to-book value (P/BV) at 3.98, the pharmaceutical and biotechnology company is increasingly viewed as an attractive proposition relative to its historical averages and peer group benchmarks.
Read More
ERIS Lifesciences Ltd Quality Grade Downgrade: A Detailed Analysis of Business Fundamentals
2026-10-28 08:00:06ERIS Lifesciences Ltd has recently seen its quality grade downgraded from good to average, reflecting shifts in key business fundamentals. Despite a strong market cap and a recent positive day change of 8.38%, the company’s underlying financial metrics reveal a mixed picture, with some improvements overshadowed by emerging concerns in profitability consistency and leverage ratios.
Read MoreAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
13-Nov-2026 | Source : BSEas attached
Announcement under Regulation 30 (LODR)-Newspaper Publication
06-Nov-2026 | Source : BSEas attached
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
04-Nov-2026 | Source : BSEas attached
Corporate Actions
No Upcoming Board Meetings
ERIS Lifesciences Ltd has declared 721% dividend, ex-date: 29 May 26
No Splits history available
No Bonus history available
No Rights history available
